Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dolby Laboratories, Inc.DLB · Entity 2518 | Director · President and CEO | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dolby Laboratories, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | Direct | 145,252 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Gift · Disposed 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | IndirectBy a trust | 145,252 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Gift · Acquired 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5.
F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter.
F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2021 Filed Mar 11, 2021 16:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-019767 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-009087 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 220,929 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,357 | $91.86 | $492,106.88 |
DisclosureSEC source: 0001209191-21-009087 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $91.42 to $92.265, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 29,457 | $91.95 | $2,708,482.78 |
DisclosureSEC source: 0001209191-21-009087 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 38,252 F1 · price: The shares were sold in multiple transactions at prices ranging from $91.37 to $92.29, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-009087 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 67,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2021 Filed Jan 19, 2021 18:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 91,597 | $0.00 Strike: $92.08 | $0.00 |
DisclosureSEC source: 0001209191-21-004103 · doc4.xml · derivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 91,597 Underlying: Class A Common Stock · 91,597 shares Expires 2030-12-15 F1 · kind: Effective January 14, 2021 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 91,597 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2020, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| January 14, 2021 Filed Jan 19, 2021 18:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 91,597 | $0.00 Strike: $92.08 | $0.00 |
DisclosureSEC source: 0001209191-21-004103 · doc4.xml · derivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 91,597 shares Expires 2030-12-15 F1 · kind: Effective January 14, 2021 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 91,597 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2020, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 17:52 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,168 | $92.07 | $475,830.16 |
DisclosureSEC source: 0001209191-20-064696 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 38,252 F3 · price: This transaction was executed in multiple trades at prices ranging from $91.48 to $92.43, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 17:52 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 5,082 | $91.03 | $462,614.46 |
DisclosureSEC source: 0001209191-20-064696 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,414 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 106,414 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 5,268 | $92.08 | $485,077.44 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,664 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F7 · balance_after: Shares held following the reported transactions include 116,664 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 1,771 | $91.61 | $162,239.01 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F6 · price: This transaction was executed in multiple trades at prices ranging from $91.165 to $92.00, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 9,768 | $90.60 | $885,023.78 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 34,666 F5 · price: This transaction was executed in multiple trades at prices ranging from $90.147 to $91.11, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 91,597 | $0.00 Strike: $92.08 | $0.00 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,597 Underlying: Class A Common Stock · 91,597 shares Expires 2030-12-15 F9 · derivative.exercise_date: This option was granted for a total of 91,597 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2020, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Restricted Stock Unit · Derivative | 21,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,394 Underlying: Class A Common Stock · 21,394 shares Expires not disclosed F8 · derivative.exercise_price: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2020 and ending December 12, 2023. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F8 · derivative.exercise_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2020 and ending December 12, 2023. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F8 · derivative.expiration_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2020 and ending December 12, 2023. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 42,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,289 F3 · acquired: Award represents a total of 42,789 restricted stock units granted under the terms of the Issuer's 2020 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 15, 2020. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F4 · balance_after: Shares held following the reported transactions include 127,289 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 19:28 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 11,349 | $90.86 | $1,031,170.14 |
DisclosureSEC source: 0001209191-20-064239 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,500 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 84,500 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 16:08 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-20-057439 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 250,386 Underlying: Class A Common Stock · 30,000 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 16:08 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 30,000 | $85.00 | $2,550,000.00 |
DisclosureSEC source: 0001209191-20-057439 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 16:08 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,000 | $37.35 | $1,120,500.00 |
DisclosureSEC source: 0001209191-20-057439 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,879 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 280,386 Underlying: Class A Common Stock · 6,879 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 23,121 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 0 Underlying: Class A Common Stock · 23,121 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 6,879 | $80.00 | $550,320.00 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 6,879 | $37.35 | $256,930.65 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 39,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 23,121 | $80.00 | $1,849,682.31 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $80.00 to $80.015, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 23,121 | $33.15 | $766,461.15 |
DisclosureSEC source: 0001209191-20-057142 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 56,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-056640 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 23,121 Underlying: Class A Common Stock · 30,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 30,000 | $75.00 | $2,250,000.00 |
DisclosureSEC source: 0001209191-20-056640 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 16:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,000 | $33.15 | $994,500.00 |
DisclosureSEC source: 0001209191-20-056640 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,832 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 53,121 Underlying: Class A Common Stock · 29,832 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 29,832 | $69.79 | $2,081,897.72 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $69.63 to $70.25, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,832 | $33.15 | $988,930.80 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 82,953 Underlying: Class A Common Stock · 50,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 50,000 | $69.90 | $3,495,060.00 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $69.32 to $70.71, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 19:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 50,000 | $33.15 | $1,657,500.00 |
DisclosureSEC source: 0001209191-20-045582 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 82,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 49,664 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · derivative · entry 10 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 132,953 Underlying: Class A Common Stock · 49,664 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| May 27, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 49,664 | $61.20 | $3,039,233.18 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $60.769 to $61.70, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 49,664 | $33.15 | $1,646,361.60 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 82,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,782 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 182,617 Underlying: Class A Common Stock · 11,782 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2015, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 38,218 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 0 Underlying: Class A Common Stock · 38,218 shares Expires 2022-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2018 was at 125% of target, or 121,498 shares. Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 11,782 | $60.00 | $706,920.00 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 11,782 | $33.15 | $390,573.30 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 44,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 38,218 | $60.00 | $2,293,080.00 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:29 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 38,218 | $33.15 | $1,266,926.70 |
DisclosureSEC source: 0001209191-20-032754 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 71,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 19:00 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 193,175 | $0.00 Strike: $68.40 | $0.00 |
DisclosureSEC source: 0001209191-20-013562 · doc4.xml · derivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 193,175 Underlying: Class A Common Stock · 193,175 shares Expires 2029-12-16 F1 · kind: Effective February 27, 2020 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 193,175 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 16, 2019, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 19:00 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 193,175 | $0.00 Strike: $68.40 | $0.00 |
DisclosureSEC source: 0001209191-20-013562 · doc4.xml · derivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 193,175 shares Expires 2029-12-16 F1 · kind: Effective February 27, 2020 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 193,175 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 16, 2019, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:02 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-008136 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 38,218 Underlying: Class A Common Stock · 5,000 shares Expires 2022-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2018 was at 125% of target, or 121,498 shares. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:02 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,000 | $71.08 | $355,416.00 |
DisclosureSEC source: 0001209191-20-008136 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $71.01 to $71.31, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:02 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 5,000 | $33.15 | $165,750.00 |
DisclosureSEC source: 0001209191-20-008136 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 37,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 20:02 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $33.15 | $0.00 |
DisclosureSEC source: 0001209191-20-008136 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 43,218 Underlying: Class A Common Stock · 50,000 shares Expires 2022-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2018 was at 125% of target, or 121,498 shares. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 20:02 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 50,000 | $72.00 | $3,599,865.00 |
DisclosureSEC source: 0001209191-20-008136 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $71.66 to $72.25, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.